Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)
Summary
The Cluster Health is under Pillar 2 of Horizon Europe. Its role is to advance knowledge and capabilities, improve understanding of health and diseases, develop innovative methodological and technological solutions to better manage health and diseases, as well as to design sustainable approaches for the digital transformation and delivery of integrated, person-centred and equitable health and care services.
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Call
Detailed Call Description
In all cases, actions should cover deep immunological phenotyping of the host response, including the use of animal models or in-vitro models if relevant. The latter should cover the dynamics of the innate and adaptive immune responses to the chosen virus(es) including, if relevant, the association of HLA assets of patients with protective or harmful immune responses. Ultimately, this research should inform disease progression and the development of personalised prophylactic and therapeutic strategies.
The analysis should address the effect of differences in age, sex, gender, ethnicity, chronic conditions, co-morbidities, treatments offered and other relevant characteristics.
Proposals that focus on COVID-19 are strongly encouraged to build links with the EU-funded project ORCHESTRA. Proposals should pay special attention and link to the newly established European COVID-19 data sharing platform and collaborate with the existing network of COVID-19 projects.
Proposals could consider the involvement of the European Commission’s Joint Research Centre (JRC) on modelling the pathogenesis of COVID-19 using Adverse Outcome Pathways.
Collaboration with other relevant initiatives, such as the International Consortium for Personalised Medicine (ICPerMed), the 1+ Million Genomes initiative and the EBrains research infrastructure is encouraged, where relevant.
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
EU contribution per project: € 7,00 million
Eligibility For Participation Notes
The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.
Programme Category
EU Competitive ProgrammesTotal Budget
€60,00 millionThematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Researchers/Research Centers/Institutions
Call Opening Date
22/06/2021Call Closing Date
21/09/2021National Contact Point(s)
Research and Innovation Foundation
Marinos Fotiadis
Contact Phone: 22 205 048
E-mail: mphotiades@research.org.cy
Website: https://www.research.org.cy/
Ioannis Theodorou
Contact Phone: 22 205 038
E-mail: itheodorou@research.org.cy
Website: https://www.research.org.cy/
(Publish Date: 03/08/2021-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact